Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells

Keith, W.N. , Thomson, C.M., Howcroft, J., Maitland, N.J. and Shay, J.W. (2007) Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells. Drug Discovery Today, 12, pp. 611-621.

Full text not currently available from Enlighten.

Abstract

Telomerase activation is a hallmark of cancer. Advancement of telomerase as a therapeutic drug target has paved the way for translational opportunities in the related fields of senescence and cancer stem cells. Here, lessons may be learnt that can be applied to drug discovery, particularly with regard to the need to appreciate the relationships between telomerase, senescence and cancer stem cells. When considered as a time line to clinical trial, targeting of telomerase is leading the way to clinical proof-of-concept, with senescence and the cancer stem cell phenotype driving research concepts vital to maintaining a clinical development pipeline.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Keith, Professor Nicol
Authors: Keith, W.N., Thomson, C.M., Howcroft, J., Maitland, N.J., and Shay, J.W.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Drug Discovery Today
ISSN:1359-6446

University Staff: Request a correction | Enlighten Editors: Update this record